- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05400265 | Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor | completed | Phase 1 | 9 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT00486356 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01206465 | Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors | completed | Phase 1 | 29 | University of NebraskaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03941262 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | completed | Phase 1 | 27 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00084734 | Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | Roswell Park Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00107250 | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | completed | Phase 1 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00357747 | AEG35156 and Docetaxel in Treating Patients With Solid Tumors | completed | Phase 1 | 10 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00372736 | AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | completed | Phase 1 | 27 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00390117 | AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00443976 | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT00504296 | SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 39 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00813423 | Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2023 | clinicaltrials |
| NCT04084951 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 30 | SQZ BiotechnologiesINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT04683354 | Study of HL-085 in Patients With Advanced Solid Tumor Tumors | completed | Phase 1 | 28 | Kechow Pharma, Inc.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT04252339 | RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 56 | Hoffmann-La RocheINDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02049593 | PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 44 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT00981162 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | completed | Phase 1 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT01924260 | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer | completed | Phase 1 | 26 | Edward KimOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04428086 | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. | completed | Phase 1 | 19 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01497392 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | completed | Phase 1 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01527136 | Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 25 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01540253 | PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic | completed | Phase 1 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | completed | Phase 1 | 53 | Cancer Research UKOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03600090 | Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer | completed | Phase 1 | 12 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03951116 | Study of FCN-437c in Patients With Advanced Solid Tumors(FCN-437c) | completed | Phase 1 | 22 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03673020 | Phase 1a Study to Evaluate Immunogenicity of ASV® | completed | Phase 1 | 3 | Agenus Inc.INDUSTRY | 1 | Dec 2, 2021 | clinicaltrials |
| NCT03147378 | Food Effect Study of ModraDoc006 in Combination With Ritonavir | completed | Phase 1 | 18 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT04014257 | A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | completed | Phase 1 | 17 | Handok Inc.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02869295 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors(NKTR-214) | completed | Phase 1 / Phase 2 | 28 | Nektar TherapeuticsINDUSTRY | 1 | Jul 29, 2021 | clinicaltrials |
| NCT03360734 | Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors(GATTO) | completed | Phase 1 | 50 | Glycotope GmbHINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT04515043 | EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) | completed | Phase 1 | 6 | InvectysINDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT03318445 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | completed | Phase 1 | 22 | Pamela MunsterOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT01169532 | Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 16 | Fox Chase Cancer CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01337765 | Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 29 | PfizerINDUSTRY | 5 | Oct 9, 2020 | clinicaltrials |
| NCT03008018 | Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours(HDAC6i) | completed | Phase 1 | 20 | Karus Therapeutics LimitedINDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT00002950 | Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 25 | Yale UniversityOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00091299 | Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00390156 | Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors | completed | Phase 1 | 35 | University of California, San FranciscoOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01470365 | 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors | completed | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT00003891 | Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 9, 2020 | clinicaltrials |
| NCT00003890 | MG98 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 19 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 6, 2020 | clinicaltrials |
| NCT00006036 | Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 14 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00645060 | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT01488513 | ABC294640 in Treating Patients With Advanced Solid Tumors(ABC-101) | completed | Phase 1 | 22 | RedHill Biopharma LimitedINDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2024source: clinicaltrials